Johnson & Johnson’s laboratory has published the results of the study of its candidate against coronavirus in the principles of next week. A list of provisional data, published in the New England Journal of Medicine, the vacancy unveiled alongside Janssen Pharmaceutical Companies, will showcase its Phase 3 results, step by step to apply for emergency use.
In an interview with the CNBC program of the United States, the finance director of the laboratory, Joseph Wolk, adelantó: “We plan to inform the results of the beginning of the next week”
The third phase of the clinical trials of the vaccine, which accounted for 45,000 people in 8 countries, potentially included cases of the new variants of coronavirus identified in South Africa and Brazil, dijo Wolk.
Last week, the director of the National Institute of Allergy and Infectious Diseases, Anthony Fauci, said that Johnson & Johnson had established proximity to the emergency use authorization for the Covid-19 vaccine in the EEU Food and Drug Administration (FDA)
The study laboratory adelanto in phase 1/2 studies a minimum response of at least 71 days in the study participants from 18 to 55 years. The so-called “Ad26.COV2.S” vaccine is administered as a single dose, which means a great deal of success over the current developments, and could provoke an acceleration in the evacuation campaigns throughout the world.
A vacancy that is sum
The Johnson & Johnson notice allows a dose number actually available considerably, at a time when the goblins increase the tensions with the labs on the backs in the entrances of the ampoules. In addition, the sanitary authorities of various countries recognize that the contagios are under control, especially with the new variants of the Sars-Cov-2.
“In terms of summit, we have a lot of confidence and we are in the truck to complete with all our compromises”, said Joseph Wolk.
In addition to these promises, the New York Times diary adelanto states that the company’s methods are “very ambitious”. According to the information, the laboratory was experimenting with retrieval during manufacture, which would reduce the amount of doses available initially.
The company runs a monthly retreat with the original production program and does not wait until the final dates of April, when it creates more than 60 million doses. following familiar characters with the help.
For the laboratory, the forecasters include 100 million doses for the United States in the final of June, around 200 million doses in the European Union, with the first enrollments in April, and around 200 million doses in developing countries. All projections that must confirm the authorization level.
A candidate with sales
Like the Pfizer / BioNTech and Moderna vehicles, it is a candidate for genetic engineering cells in the human body cells to create a specific protein for the coronavirus, which it must train in the immunological system to respond appropriately.
However, the technology used by Johnson & Johnson differs from Pfizer and Modern, and is similar to the one used for the AstraZeneca, Sputnik and CanSino vacancies, referred to as “adenoviral vector vacancies”. The three have a large storage capacity: can be stored at normal refrigerator temperature.
Pfizer and Moderna use ARN messenger molecules, while the stadium’s vacancy displays a double cadence DNA that is stored in ARN inside the human cells to launch the same object.
A vacancy for Argentina and Uruguay?
The Argentine Minister of Health, Ginés González García, revealed the existence of conversations with Janssen, owned by Johnson & Johnson, for which a notice on good results could generate expectant attention in some anti-money laundering plans and current marches.
In addition, this vacancy is part of the roads in the South American country. The company celebrates the participation of Argentine volunteers, as well as the existence of scientific societies, Paula Barreyro, Director of Medical and Regulatory Assistance for Janssen Latinoamérica Sur.
If negotiations are well underway, Alberto Fernández’s governor has not provided detailed dose information yet, although it is known that the possible price is 37 dollars.
For his part, the governor of Uruguay’s president, Luis Lacalle Pou, who agreed with Pfizer and Sinovac, hopes for the ultimate results of the “J&J” efforts to conclude an operation with the stadium.